Zwolle

• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• A phase 2 trial in stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab - TURANDORELA Recruiting
  2023-507460-39-00 10 2024-02-15 Adult patients with resectable muscle-invasive urothelial cancer of th
• PREMI trial Recruiting
  2023-503220-76-01 6 2024-02-13 Unexplained recurrent miscarriages
• A study to investigate the effect of adding cobicistat to venetoclax and azacitidine in patients with acute myeloid leukemia (AML) who are i … Recruiting
  2023-505379-61-00 4 2024-01-17 Acute Myeloid Leukaemia
• The RiCOTTA study: Rifampicin Combination Therapy versus Targeted Antibiotic Monotherapy for Infected Joint Prostheses Caused by Staphylococ … Recruiting
  2022-501620-26-00 6 2023-05-15 prosthetic joint infection
• WOEST-3 Recruiting
  2022-502140-13-00 6 2023-01-11 Atrial fibrillation Acute coronary syndrome Chronic coronary syndrome
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital
• Prevention of opioid-induced constipation in patients with advanced cancer. Recruiting
  2023-509462-38-00 11 2022-10-25 Patients with advanced cancer.
• Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus … Recruiting
  2024-512526-28-00 5 2020-10-28 Locally recurrent rectal cancer
• Doxapram versus placebo in preterm newborns: An international double blinded multicenter randomized controlled trial Recruiting
  2024-515625-29-00 5 2020-06-16 Apnea of prematurity
• DRUP trial Recruiting
  2023-509152-33-00 4 2016-07-25 Advanced solid tumor
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended recruitment
  2024-512998-27-00 5 2025-02-21 Non-Small Cell Lung Cancer
• Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P … Ended recruitment
  2024-518171-59-00 11 2025-01-23 Prostate Cancer
• Prevention of the return of nephrotic syndrom in children by adding levamisole to prednisolone treatment Ended recruitment
  2024-517467-23-00 5 2024-11-29 steroid sensitive idiopathic nephrotic syndrome
• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive … Ended recruitment
  2024-510908-37-00 5 2024-08-28 KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
• Comparison of targeted radiotherapy with and without short-term hormonal treatment (6 months) Ended recruitment
  2024-511252-41-00 5 2024-07-30 Patients with biochemical recurrence after primary treatment of prosta
• Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended recruitment
  2024-513105-31-00 6 2024-07-30 Multiple Sclerosis
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended recruitment
  2023-503312-32-00 4 2024-06-24 Esophageal squamous cell carcinoma
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• Safe, effective and cost-effective oxygen saturation targets for children and adolescents with respiratory distress: a randomized controlled … Ended recruitment
  2023-504817-56-00 6 2023-09-05 Bronchiolitis

Showing 97–120 of 191 trials